A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema Council

Abstract

The decision to initiate JAKi treatment should be shared between the patient and provider, accounting for AD severity and personal risk-benefit assessment, including consideration of baseline health risk factors, monitoring requirements and treatment costs.